Doug Troy Joins Two Labs as New Chief Operating Officer
At Two Labs, we value partnership. We work hard to make sure our clients view us as an extended part of their team, and not just another vendor. As the pharma market continues to evolve, we are excited to expand [...]
Two Labs Joins Global Celebration of Rare Disease Day
Since 2008, Rare Disease Day has been on the last day of February – which every four years is a rare 29th of the month. The observance was created to drive awareness of the 6,000 existing rare diseases [...]
Current and Future Oncology Management in the United States
The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. [...]
Innovative Access Agreements
A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have [...]
Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market
Although biosimilars have taken off in Europe, they have yet to gain significant traction in the United States. More than thirty biosimilars have been approved and twenty-six are marketed in Europe. In the US, there are only eleven biosimilars [...]
Two Labs Acquires Pennside Partners Ltd.
We’re excited to share today that as of October 18, 2018, Two Labs has acquired Pennside Partners Ltd., a leading international provider of market insights, benchmarking, and competitive intelligence services for the pharmaceutical, biotech, and medical device sectors. This [...]